A Randomized, Open Label, Multicentric Phase III [study] Evaluating the Benefit of a Sequential Regimen Associating FEC 100 [fluorouracil + epirubicin + cyclophosphamide] and Ixabepilone in Adjuvant Treatment of Non Metastatic, Poor Prognosis Breast Cancer Defined as Triple-Negative Tumor [HER2 Negative - ER Negative - PR Negative] or [HER2 Negative and PR Negative] Tumor; in Node Positive or Node Negative Patients.

Trial Profile

A Randomized, Open Label, Multicentric Phase III [study] Evaluating the Benefit of a Sequential Regimen Associating FEC 100 [fluorouracil + epirubicin + cyclophosphamide] and Ixabepilone in Adjuvant Treatment of Non Metastatic, Poor Prognosis Breast Cancer Defined as Triple-Negative Tumor [HER2 Negative - ER Negative - PR Negative] or [HER2 Negative and PR Negative] Tumor; in Node Positive or Node Negative Patients.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Docetaxel (Primary) ; Ixabepilone (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
  • Indications Early breast cancer
  • Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms TavIx
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 03 May 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2019.
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top